United States of America based
The different approaches used by InveniAI to disrupt the status quo and solve complex problems in Healthcare, Drug Discovery & Development applications are exemplified in its EvolverAI and PharmGPS® platforms.
EvolverAI is InveniAI's augmented intelligence platform that combines human intuition based on experience and expertise with the comprehensiveness and scale of artificial intelligence. EvolverAI combines Big Data technology with machine learning to present to human experts massive and complex data sets in a manner that allow us humans to decipher patterns and enables the generation of hypotheses. EvolverAI combines the tenets of deductive, inductive and abductive research in this journey of discovery.
PharmGPS® is InveniAI's Big Data platform applied to understanding how drugs work and which of them are useful in satisfying unmet medical needs. PharmGPS® has collated and crystallized the cumulative wisdom of pharmaceutical and drug development research to identify the drugs that are most likely to succeed in the regulatory process and satisfy patients’ needs. It utilizes machine learning and big data approaches to predict future potential of drugs that are still in early stages of clinical development.
TechnologiesAI Companies (Drug Discovery)
Posts Mentioning This Company
Big Data to Therapeutic Leads
Take the Next Step in the Path Towards Success in Drug Development
We are actively decoding the gut-brain axis (GBA) as a therapeutic target for various gastrointestinal disorders. The GBA is a bidirectional communication network between the central nervous system (CNS) and the gastrointestinal (GI) tract and is key to maintaining good health. A disturbance of this status is often referred to as gut dysbiosis. Neurotransmitter cells in the gut also play an essential role in relaying messages from the brain to the gut (afferent signals) and the gut to the brain (efferent signals) and play an essential role in mediating the immune response to gut dysbiosis or other sources of inflammation (neuroinflammation). In chronic inflammatory diseases, this causes a “runaway immune response,” leading to a chronic inflammatory state.
Harnessing the GBA to identify key immune and signaling players (pathways and targets) that cause neuroinflammation will ultimately lead to a better understanding of gut dysbiosis, how homeostasis can be restored, and the treatment of certain GI and CNS disorders.
AlphaMeld® is powering a comprehensive association analysis of the GBA and inflammasome by leveraging millions of data points to generate hypotheses across the pathophysiological processes of inflammatory gut diseases from induction, remission, mucosal healing, and fibrosis. AlphaMeld has generated multiple hypotheses with demonstrated safety. All programs discovered and validated by InveniAI will be further developed by Invea Therapeutics, the clinical development subsidiary of InveniAI LLC.
No services posted yet